Clinical correlations with CXCL13 were performed by investigating the disease-free survival (DFS) of 794 breast cancer patients, which revealed that CXCL13 expression was positively correlated with DFS in breast cancer, especially in the human epidermal growth factor 2 (HER2+) group. Here, ERBB2 is linked to breast cancer.